ESCAPE Bio to Present at the Stifel 2020 Virtual Healthcare Conference
Date: Monday, November 16, 2020
Time: 2:40 p.m. ET
URL to Access Webcast: https://wsw.com/webcast/stifel27/esbi/2073328
About ESCAPE Bio
ESCAPE Bio is a clinical stage, privately held biopharmaceutical company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases. ESB1609 is in a Phase 1 multiple ascending dose study in healthy volunteers. ESCAPE has advanced a mutant-selective LRRK2 G2019S kinase inhibitor for Parkinson’s Disease (PD) patients to IND-enabling studies. A pharmacologic structure corrector of Alzheimer's patients carrying the ApoE4 risk allele is in Discovery. For additional information, please visit www.escapebio.com.
Source: ESCAPE Bio Inc.